INSM
Insmed
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
consensus rating "Strong Buy"
EPS Below Expectations
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About INSM
Insmed Incorporated
A biopharmaceutical company focused on developing and commercializing innovative therapies for rare and serious diseases
700 US Highway 202/206, Bridgewater, New Jersey 08807
--
Insmed Incorporated is a biopharmaceutical company focused on developing inhaled therapies to combat life-threatening lung diseases for patients. The company's flagship products ARIKACE and amikacin liposome inhalation are an inhaled antibiotic therapy, proving that anti-infectives can improve the efficacy, safety and convenience of the therapy in the treatment of severe lung infections. The company was established in Commonwealth Virginia on November 29, 1999.
Company Financials
EPS
INSM has released its 2024 Q4 earnings. EPS was reported at -1.32, versus the expected -1.16, missing expectations. The chart below visualizes how INSM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
INSM has released its 2024 Q4 earnings report, with revenue of 104.44M, reflecting a YoY change of 24.79%, and net profit of -235.55M, showing a YoY change of -26.60%. The Sankey diagram below clearly presents INSM’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
